Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 8, 2016

Primary Completion Date

June 6, 2017

Study Completion Date

June 10, 2017

Conditions

Healthy

Interventions

DRUG

JNJ-63623872

3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

DRUG

Placebo

Intravenous infusion of matching placebo.

Trial Locations (1)

Merksem